Lebwohl M, Gooderham M, Warren RB, Thaçi D, Foley P, Gottlieb AB, Hippeli L, Kisa RM, Banerjee S, Griffiths CE. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. J of Skin [Internet]. 2023 Nov. 13 [cited 2024 Jul. 3];7(6):s239. Available from: https://jofskin.org/33014/index.php/skin/article/view/2361